In this paper, we explain what proportional approach to technology appraisals (PATT) and streamlined cost-comparison appraisals (sCCA) are and their relevance to the HTA and reimbursement of medicinal products in the UK. We then look at what we have learned so far from the first 15 sCCAs, consider the potential impact for manufacturers, and provide guidance on how they can best prepare for NICE appraisal when sCCA is an option.

Fill out the form on the right to download the paper.

Download the paper

"*" indicates required fields

Sign me up to receive regular insights from Lumanity
By selecting this box, I consent to receive Lumanity marketing communications by email.
This field is for validation purposes and should be left unchanged.